63 related articles for article (PubMed ID: 16498555)
21. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
Bäck M; Yin L; Ingelsson E
Eur Heart J; 2012 Aug; 33(15):1928-33. PubMed ID: 22108833
[TBL] [Abstract][Full Text] [Related]
22. Etoricoxib-induced acute generalized exanthematous pustulosis.
Mäkelä L; Lammintausta K
Acta Derm Venereol; 2008; 88(2):200-1. PubMed ID: 18311467
[No Abstract] [Full Text] [Related]
23. Merck's Careful Study of Vioxx.
Mayer TV
Am J Cardiol; 2008 Apr; 101(7):1068-9; author reply 1069. PubMed ID: 18359336
[No Abstract] [Full Text] [Related]
24. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.
Andersohn F; Schade R; Suissa S; Garbe E
Stroke; 2006 Jul; 37(7):1725-30. PubMed ID: 16728684
[TBL] [Abstract][Full Text] [Related]
25. The withdrawal of rofecoxib.
Arellano FM
Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):213-7. PubMed ID: 15724267
[No Abstract] [Full Text] [Related]
26. The patient's perspective on the recall of Vioxx.
Hawker GA; Katz JN; Solomon DH
J Rheumatol; 2006 Jun; 33(6):1082-8. PubMed ID: 16755654
[TBL] [Abstract][Full Text] [Related]
27. Etoricoxib-induced erythema-multiforme-like eruption.
Thirion L; Nikkels AF; Piérard GE
Dermatology; 2008; 216(3):227-8. PubMed ID: 18182814
[TBL] [Abstract][Full Text] [Related]
28. Adverse cardiovascular effects of rofecoxib.
Furberg CD
N Engl J Med; 2006 Jul; 355(2):204; author reply 204-5. PubMed ID: 16838442
[No Abstract] [Full Text] [Related]
29. Adverse cardiovascular effects of rofecoxib.
Nissen SE
N Engl J Med; 2006 Jul; 355(2):203-4; author reply 203-5. PubMed ID: 16801355
[No Abstract] [Full Text] [Related]
30. The Vioxx® legacy: Enduring lessons from the not so distant past.
McIntyre WF; Evans G
Cardiol J; 2014; 21(2):203-5. PubMed ID: 24752949
[No Abstract] [Full Text] [Related]
31. [Rapidly acting and powerful antirheumatic drug now also approved in Germany. Arcoxia (etoricoxib, MSD)]].
Krankenpfl J; 2004; 42(7-10):238. PubMed ID: 15675401
[No Abstract] [Full Text] [Related]
32. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
Moore RA; Derry S; McQuay HJ
BMC Musculoskelet Disord; 2007 Aug; 8():73. PubMed ID: 17683540
[TBL] [Abstract][Full Text] [Related]
33. What have we learnt from Vioxx?
Krumholz HM; Ross JS; Presler AH; Egilman DS
BMJ; 2007 Jan; 334(7585):120-3. PubMed ID: 17235089
[TBL] [Abstract][Full Text] [Related]
34. COX-2 selective inhibitors and heart health.
Simon LS; White WB
Postgrad Med; 2005 Jan; 117(1 Suppl):7-20. PubMed ID: 19667717
[TBL] [Abstract][Full Text] [Related]
35. Oral etoricoxib for pain relief during fractional curettage: a randomized controlled trial.
Phittayawechwiwat W; Thanantaseth C; Ayudhya NI; O-Prasertsawat P; Kongprasert J
J Med Assoc Thai; 2007 Jun; 90(6):1053-7. PubMed ID: 17624196
[TBL] [Abstract][Full Text] [Related]
36. Life after Vioxx.
Underwood A
Newsweek; 2005 Jan; 145(5):40-1. PubMed ID: 17896720
[No Abstract] [Full Text] [Related]
37. Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs.
Roth-Cline MD
Circulation; 2006 May; 113(18):2253-9. PubMed ID: 16684875
[No Abstract] [Full Text] [Related]
38. [Pain treatment with traditional NSAR and coxibs: an interdisciplinary assessment].
Fischbach W; Baerwald C; Darius H; Gross M; Nickenig G; Nüßlein H; Stichtenoth DO
Dtsch Med Wochenschr; 2013 Jan; 138(3):91-6. PubMed ID: 23299345
[No Abstract] [Full Text] [Related]
39. Cardiovascular issues of COX-2 inhibitors and NSAIDs.
Wong M; Chowienczyk P; Kirkham B
Aust Fam Physician; 2005 Nov; 34(11):945-8. PubMed ID: 16299629
[TBL] [Abstract][Full Text] [Related]
40. How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as "punching bag".
Armstrong D
Wall St J (East Ed); 2006 May; ():A1, A10. PubMed ID: 16848016
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
